Magram has over 20 years of drug discovery and development experience. She was the founding chief scientific officer of Northern Biologics, a Toronto Canada based biotechnology company. Prior to Northern Biologics, she served as the site head for Pfizer's Centers for Therapeutic Innovation, New York.
Previously, Magram was vice president, immunology and inflammation research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease.
Prior to Boehringer Ingelheim, she was an associate director of G protein-coupled receptor drug discovery at OSI Pharmaceuticals. She also previously spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.
Magram completed her postdoctoral training in the laboratory of Nobel Laureate J. Michael Bishop, M.D. at the University of California, San Francisco School of Medicine and obtained her Ph.D. in the laboratory of Franklin Costantini, Ph.D. in the Department of Genetics and Development at Columbia University Irving Medical Center.
Privately held Quentis Therapeutics is pursuing first-in-class endoplasmic reticulum stress response-targeted therapies to address serious diseases such as cancer.
The company is pioneering the use of ER stress response modulators to boost the immune system's ability to fight cancer and to help more cancer patients benefit from immunotherapy. Its lead program is a first-in-class, small molecule, IRE1α inhibitor.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients